These guidelines suggest evaluation, therapy, and work-up of pneumonia patients based upon patient- specific risk factors, age and site of treatment. Pneumococcal species are the most common ...

Aug. 6, 2024 — An AI-based analysis of over 2 million hospital visits has found that most of the time, a pneumonia diagnosis made in the hospital will change from a patient's entrance to their ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

Stimulant medications are considered the first-line treatment for ADHD for some very good reasons. Here are 6 things to know about stimulant medications in ADHD. Attention Deficit Hyperactivity ...

Older adults are also more likely to be on chronic medications, like antipsychotics or anticholinergics, that increase the risk of pneumonia while masking the symptoms, such as coughing. In adults ...

Zydus Lifesciences Ltd share price was down by -0.64% from the previous closing price of ₹995.50. Who are peers of Zydus Lifesciences Ltd? The peers of Zydus Lifesciences Ltd are Sun ...

Zydus Lifesciences Limited (Formerly known as ... a possible collaboration in the development of a cocktail for the treatment of rabies, through the use of monoclonal antibodies.The Board of ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Zydus Lifesciences's Usnoflast receives Orphan Drug Designation from the USFDA for the treatment of Amyotrophic Lateral Sclerosis (ALS), a rare neurodegenerative disease. New Delhi, Jan 22 (PTI) Zydus ...

Beyond Cancer: Confronting the Challenges of Survivorship In this series, experts from Duke Cancer Institute discuss how the integration of cancer treatment and primary care is improving patient ...